Edition:
United States

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

73.32CNY
23 Feb 2018
Change (% chg)

¥0.85 (+1.17%)
Prev Close
¥72.47
Open
¥72.98
Day's High
¥74.88
Day's Low
¥72.43
Volume
9,661,952
Avg. Vol
13,248,498
52-wk High
¥78.75
52-wk Low
¥41.21

Latest Key Developments (Source: Significant Developments)

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis
Friday, 5 Jan 2018 02:40am EST 

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302 .Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan.Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Wednesday, 29 Nov 2017 05:44am EST 

Nov 29(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration.Company will be able to sell its Dexmedetomidine Hydrochloride Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine gets approval for clinical trials of drugs
Tuesday, 7 Nov 2017 03:32am EST 

Nov 7 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration.  Full Article

Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y
Wednesday, 18 Oct 2017 06:17am EDT 

Oct 18 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million).  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Tuesday, 5 Sep 2017 03:05am EDT 

Sept 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration .Says the company will be able to sell its cisatracurium besilate injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y
Tuesday, 29 Aug 2017 03:40am EDT 

Aug 29 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million).  Full Article

Jiangsu Hengrui Medicine and unit plans clinical trail for new drug SHR0302
Tuesday, 15 Aug 2017 04:50am EDT 

Aug 15(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it and unit plans to start clinical trail for new drug SHR0302, which is a kind of selective depressant used for treatment of rheumatoid arthritis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Tuesday, 15 Aug 2017 04:32am EDT 

Aug 15(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration .* Docetaxel Injection can be used for treatment of mammary cancer, nonsmall-cell lung cancer, prostatic cancer, gastric cancer as well as head and neck SCC.* Company will be able to sell its Docetaxel Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine's main product enters into National health insurance's list
Friday, 21 Jul 2017 05:15am EDT 

July 21(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says its main product ApatinibMesylate Tablets, a oral absorption, has been listed on National health insurance's list .  Full Article

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES